Cargando…

Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol

INTRODUCTION: Polycystic ovary syndrome (PCOS) is a heterogeneous reproductive endocrine disorder. Several ongoing trials test sodium-glucose cotransporter-2 (SGLT-2) inhibitors for women with PCOS. However, their effectiveness has not been fully elucidated owing to the lack of high-confidence evide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiaqi, Xing, Chuan, He, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039375/ https://www.ncbi.nlm.nih.gov/pubmed/35470198 http://dx.doi.org/10.1136/bmjopen-2021-058260

Ejemplares similares

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
por: Pruett, Jacob E., et al.
Publicado: (2023)

Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial
por: Zhang, Jiaqi, et al.
Publicado: (2022)

A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
por: Sinha, Binayak, et al.
Publicado: (2022)

Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome
por: Xing, Chuan, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinical–biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study
por: Reyes-Muñoz, Enrique, et al.
Publicado: (2016)

Sodium-glucose Cotransporter-2 Inhibitors and Euglycaemic Diabetic Ketoacidosis in the Perioperative Period: Case Report
por: Jhaveri, Urmita, et al.
Publicado: (2019)

A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
por: Chaurasia, Pallavi Prakash, et al.
Publicado: (2021)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Case Report and Review of Literature
por: Aggarwal, Ankita, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Followed by Excessively Low Carbohydrate Diet
por: Tsutsui, Erika, et al.
Publicado: (2021)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers
por: Somagutta, Manoj R, et al.
Publicado: (2021)

Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
por: Hussain, Mazhar, et al.
Publicado: (2021)

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia
por: Somaili, Mohammed, et al.
Publicado: (2022)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome
por: Saleem, Fatima, et al.
Publicado: (2017)

Euglycemic Diabetic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor Use Post-Bariatric Surgery: A Brief Review of the Literature
por: Iqbal, Qasim Z, et al.
Publicado: (2020)

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor
por: Sugiyama, Seigo, et al.
Publicado: (2020)

Postoperative Euglycemic Ketoacidosis in Type 2 Diabetes Associated with Sodium-Glucose Cotransporter 2 Inhibitor: Insights Into Pathogenesis and Management Strategy
por: Chandrakumar, Harshith P, et al.
Publicado: (2021)

A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Patel, Khyati, et al.
Publicado: (2022)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Endocrine and metabolic interactions in healthy pregnancies and hyperinsulinemic pregnancies affected by polycystic ovary syndrome, diabetes and obesity
por: Neven, Adriana C. H., et al.
Publicado: (2023)

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
por: Beitelshees, Amber L., et al.
Publicado: (2019)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

Effects of TCM on polycystic ovary syndrome and its cellular endocrine mechanism
por: Chen, Huize, et al.
Publicado: (2023)

Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review
por: Elshimy, Ghada, et al.
Publicado: (2019)

Frequency of Subclinical Hypothyroidism in Women With Polycystic Ovary Syndrome
por: Raj, Deepak, et al.
Publicado: (2021)

A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions
por: Emanuel, Rebecca H. K., et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
por: Lai, Shih-Wei, et al.
Publicado: (2023)

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2021)

Glucose and Lipid Profiles of Overweight and Obese Children in Riyadh, Saudi Arabia
por: AlAteeq, Mohammed A, et al.
Publicado: (2023)

An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials
por: Sun, Jie, et al.
Publicado: (2015)

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol
por: Hussein, Humaira, et al.
Publicado: (2018)

Type 2 Diabetes Mellitus in Patients With Polycystic Ovary Syndrome
por: Agrawal, Anjali, et al.
Publicado: (2023)

Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome
por: Yu, Jin, et al.
Publicado: (2023)

Time-restricted feeding improves metabolic and endocrine profiles in mice with polycystic ovary syndrome
por: Han, Yan, et al.
Publicado: (2022)

Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor
por: Acevedo-Mendez, Bernardo A, et al.
Publicado: (2021)

Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes
por: Stinkens, Kirsten, et al.
Publicado: (2016)

Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome
por: Wang, Dongxu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vosro3b525dpnqmso76vp7p4pv